Category: Exactech Inc.
Here's a look at some of the top personnel stories for medical device companies this week.
Malta regulators announced this week that healthcare titan Baxter plans to add 30 additional jobs in the country.
Stephen Fanning, the former CEO of Solta Medical, is Z-Medica's new chief.
Z-Medica said it named Stephen Fanning, the former CEO of Solta Medical, to be its new chief executive.
Wallingford, Conn.-based Z-Medica is developing blood clotting technologies it calls QuikClot.
Exactech beats Wall Street expectations with its 3rd-quarter results and raises its earnings outlook for the rest of the year.
Exactech (NSDQ:EXAC) beat Wall Street's expectations with its 3rd-quarter earnings and adjusted its outlook for the rest of the year.
Insulet Corp. hires the former director of Clinical Research & Technology for the Sansum Diabetes Research Institute, Dr. Howard Zisser, as its 1st medical director.
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Smith & Nephew wants rival orthopedics devices maker Exact Surgical to pay $1 million for "willful and intentional" violations of a former sales rep's non-compete and nondisclosure agreements.
Orthopedic titan Smith & Nephew (FTSE:SN, NYSE:SNN) sued rival device maker Exact Surgical for $1 million dollars for hiring a former S&M rep to sell orthopedic devices in Texas.
Thoratec leaves Wall Street analysts in the dust with its 1st quarter earnings, beating expectations by 10¢, but the initial bump fades as investors back off after sending shares up more than 7% this morning; also, Allergan's Q1 sales rise, earnings soar; Endologix's sales spike, losses soar; Q1 profits plunge for Greatbatch; Hospira's Q1 sales slip, earnings slide; ResMed's Q3 sales, earnings up; and more.
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
, Cardica Inc.
, Dentsply International Inc.
, Digirad Corp.
, DJO Global Inc.
, Endologix Inc.
, Greatbatch Inc.
, Hamilton Thorne Inc.
, Hospira Inc.
, ResMed Inc.
, Thoratec Corp.
, Allergan Inc.
Medtronic enrolls the initial patient into its Medtronic Registry for Epilepsy to look at the long-term efficacy and safety of deep brain stimulation therapy for patients with drug-resistant epilepsy.
MASSDEVICE ON CALL — As neuromodulation therapy celebrates its 25th year, Medtronic (NYSE:MDT) enrolled the 1st patient into its Medtronic Registry for Epilepsy, a database tracking the safety, efficacy and quality of life of patients receiving deep-brain stimulation for treatment of drug-resistant epilepsy.